Keilani Mohammad, Steiner Margarete, Sternik Julia, Schmeckenbecher Jim, Zwick Ralf Harun, Wagner Barbara, Crevenna Richard
Department of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Therme Wien Med, Ludwig Boltzmann Institute for Rehabilitation Research, Vienna, Austria.
Wien Klin Wochenschr. 2025 Mar 17. doi: 10.1007/s00508-025-02522-w.
The aim of this randomized, single-blinded, placebo-controlled pilot study was to explore the feasibility, acceptance and effects of pulsed electromagnetic field therapy (PEMF) in patients with post-COVID-19 fatigue syndrome.
A total of 20 patients were included in the study. They were randomly assigned to an intervention group (n = 10, male:female = 4 : 5, age = 45 ± 9 years) and a placebo group (n = 10, m:f = 4:6, age: 39 ± 23 years). A Papimi™ Delta professional electromagnetic field therapy device was used for treatment. Controls received a placebo PEMF. In total 10 PEMF sessions (30 min., 2× per week) were applied. Physical performance, health-related quality of life, fatigue, work ability, sleep, pain, anxiety and depression were assessed at baseline, posttreatment and at follow-up 5 weeks after treatment. Feasibility and acceptance were assessed posttreatment.
The intervention group showed a notable improvement in the 6 minutes walking test. The use of PEMF improved fatigue (measured with the Brief Fatigue Inventory and the Multidimensional Fatigue Inventory). Also, the depression subscale of the Hospital Anxiety and Depression Scale, the Insomnia Severity Index, the Work Ability Index and most subscales of the Short Form (SF) 36 questionnaire showed improvement. From the placebo group three patients dropped out. There were no drop-outs in the intervention group. In the intervention group, PEMF was well-accepted and patients showed very good adherence.
The results of this pilot study indicate that PEMF is feasible and well accepted. Furthermore, this study population showed improvements in physical and mental health in the intervention group. This study is a promising contribution to this growing research field and provides the required evidence for future efficacy studies on PEMF for post-COVID-19 patients.
这项随机、单盲、安慰剂对照的试点研究旨在探讨脉冲电磁场疗法(PEMF)对新冠后疲劳综合征患者的可行性、可接受性和疗效。
共有20名患者纳入本研究。他们被随机分为干预组(n = 10,男:女 = 4:5,年龄 = 45 ± 9岁)和安慰剂组(n = 10,男:女 = 4:6,年龄:39 ± 23岁)。使用Papimi™ Delta专业电磁场治疗设备进行治疗。对照组接受安慰剂PEMF。总共进行了10次PEMF治疗(每次30分钟,每周2次)。在基线、治疗后和治疗后5周的随访中评估身体机能、健康相关生活质量、疲劳、工作能力、睡眠、疼痛、焦虑和抑郁情况。治疗后评估可行性和可接受性。
干预组在6分钟步行试验中显示出显著改善。使用PEMF改善了疲劳(用简易疲劳量表和多维疲劳量表测量)。此外,医院焦虑抑郁量表的抑郁分量表、失眠严重程度指数、工作能力指数和简短健康调查问卷(SF-36)的大多数分量表均有改善。安慰剂组有3名患者退出。干预组无退出者。在干预组中,PEMF被很好地接受,患者表现出非常好的依从性。
这项试点研究的结果表明,PEMF是可行的且易于接受。此外,该研究人群在干预组中显示出身心健康的改善。这项研究为这个不断发展的研究领域做出了有前景的贡献,并为未来针对新冠后患者的PEMF疗效研究提供了所需的证据。